SEARCH

SEARCH BY CITATION

References

  • 1
    Tavassoli FA, Devilee P, International Agency for Research on Cancer, World Health Organization. Pathology and genetics of tumours of the breast and female genital organs. Lyon: IARC Press, 2003.
  • 2
    Harris JR. Diseases of the breast, 4th ed. Philadelphia: Lippincott Williams & Wilkins, 2010.
  • 3
    Lakhani SR, International Agency for Research on Cancer, World Health Organization. WHO classification of tumours of the breast, 4th edn. Lyon: International Agency for Research on Cancer, 2012.
  • 4
    Gnant M, Harbeck N, Thomssen C. St. Gallen 2011summary of the consensus discussion. Breast Care (Basel) 2011; 2011; 136141.
  • 5
    Hammond ME, Hayes DF, Dowsett M et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J. Clin. Oncol. 2010; 28; 27842795.
  • 6
    Guiu S, Michiels S, Andre F et al. Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement. Ann. Oncol. 2012; 23; 29973006.
  • 7
    Goldhirsch A, Wood WC, Coates AS et al. Strategies for subtypes – dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer. Ann. Oncol. 2011; 2011; 17361747.
  • 8
    Nielsen TO, Hsu FD, Jensen K et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin. Cancer Res. 2004; 10; 53675374.
  • 9
    Parker JS, Mullins M, Cheang MC et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J. Clin. Oncol. 2009; 27; 11601167.
  • 10
    Prat A, Cheang MC, Martin M et al. Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. J. Clin. Oncol. 2013; 31; 203209.
  • 11
    Hu Z, Fan C, Oh DS et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 2006; 7; 96.
  • 12
    Sorlie T, Tibshirani R, Parker J et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl Acad. Sci. USA 2003; 100; 84188423.
  • 13
    Perry N, Broeders M, de Wolf C, Tornberg S, Holland R, von Karsa L. European guidelines for quality assurance in breast cancer screening and diagnosis, 4th edition– summary document. Ann. Oncol. 2008; 19; 614622.
  • 14
    Aebi S, Davidson T, Gruber G, Cardoso F, Group EGW. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2011; 22 (Suppl. 6); vi12vi24.
  • 15
    Goldhirsch A, Winer EP, Coates AS et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann. Oncol. 2013; 9; 22062223.
  • 16
    Grabau D (ed) Quality- and Standardization Committee (KVAST) tSPS. Quality- and standardization document for breast tumors. Alingsås, Sweden: Swedish Pathological Society/Swedish Society of Clinical Cytology; 2012; 118.
  • 17
    Bergh J, Bergkvist L, Jönsson P-E et al. National guidelines for the treatment of breast cancer. In Emdin SB, Bergkvist J, Jönsson L, P-E eds. Nationella riktlinjer för behandling av bröstcancer at swebcg.se Stockholm, Sweden: Swedish Breast Cancer Group, 2008; 1128.
  • 18
    Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998; 351; 14511467.
  • 19
    Goldhirsch A, Ingle JN, Gelber RD et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann. Oncol. 2009; 20; 13191329.
  • 20
    Vielh P, Chevillard S, Mosseri V, Donatini B, Magdelenat H. Ki67 index and S-phase fraction in human breast carcinomas. Comparison and correlations with prognostic factors. Am. J. Clin. Pathol. 1990; 94; 681686.
  • 21
    Nishimura R, Osako T, Okumura Y, Hayashi M, Arima N. Clinical significance of Ki-67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosis. Breast Cancer 2010; 17; 269275.
  • 22
    Strand C, Bak M, Borgquist S et al. The combination of Ki67, histological grade and estrogen receptor status identifies a low-risk group among 1,854 chemo-naive women with N0/N1 primary breast cancer. Springerplus 2013; 2; 111.
  • 23
    Cheang MC, Chia SK, Voduc D et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J. Natl Cancer Inst. 2009; 101; 736750.
  • 24
    Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 2005; 353; 16591672.
  • 25
    Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 2005; 353; 16731684.
  • 26
    Yu YH, Wei W, Liu JL. Diagnostic value of fine-needle aspiration biopsy for breast mass: a systematic review and meta-analysis. BMC Cancer 2012; 12; 41.
  • 27
    Alkuwari E, Auger M. Accuracy of fine-needle aspiration cytology of axillary lymph nodes in breast cancer patients: a study of 115 cases with cytologic–histologic correlation. Cancer 2008; 114; 8993.
  • 28
    Manfrin E, Falsirollo F, Remo A et al. Cancer size, histotype, and cellular grade may limit the success of fine-needle aspiration cytology for screen-detected breast carcinoma. Cancer 2009; 117; 491499.
  • 29
    Dede DS, Gumuskaya B, Guler G, Onat D, Altundag K, Ozisik Y. Evaluation of changes in biologic markers ER, PR, HER 2 and Ki-67 index in breast cancer with administration of neoadjuvant dose dense doxorubicin, cyclophosphamide followed by paclitaxel chemotherapy. J. BUON 2013; 18; 366371.
  • 30
    Sethi D, Sen R, Parshad S, Khetarpal S, Garg M, Sen J. Histopathologic changes following neoadjuvant chemotherapy in locally advanced breast cancer. Indian. J. Cancer 2013; 50; 5864.
  • 31
    von Minckwitz G, Schmitt W, Loibl S et al. Ki67 measured after neoadjuvant chemotherapy for primary breast cancer. Clin. Cancer Res. 2013; 19; 45214531.
  • 32
    Lorgis V, Algros MP, Villanueva C et al. Discordance in early breast cancer for tumour grade, estrogen receptor, progesteron receptors and human epidermal receptor-2 status between core needle biopsy and surgical excisional primary tumour. Breast 2011; 20; 284287.
  • 33
    Cahill RA, Walsh D, Landers RJ, Watson RG. Preoperative profiling of symptomatic breast cancer by diagnostic core biopsy. Ann. Surg. Oncol. 2006; 13; 4551.
  • 34
    Arnedos M, Nerurkar A, Osin P, A'Hern R, Smith IE, Dowsett M. Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC). Ann. Oncol. 2009; 20; 19481952.
  • 35
    Sofiadis A, Tani E, Foukakis T et al. Diagnostic and prognostic potential of MIB-1 proliferation index in thyroid fine needle aspiration biopsy. Int. J. Oncol. 2009; 35; 369374.
  • 36
    Nadji M, Gomez-Fernandez C, Ganjei-Azar P, Morales AR. Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers. Am. J. Clin. Pathol. 2005; 123; 2127.
  • 37
    Khoshnoud MR, Lofdahl B, Fohlin H et al. Immunohistochemistry compared to cytosol assays for determination of estrogen receptor and prediction of the long-term effect of adjuvant tamoxifen. Breast Cancer Res. Treat. 2011; 126; 421430.
  • 38
    Early Breast Cancer Trialists' Collaborative G. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365; 16871717.
  • 39
    Early Breast Cancer Trialists' Collaborative G, Davies C, Godwin J, Gray R et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011; 378; 771784.
  • 40
    Early Breast Cancer Trialists' Collaborative G, Peto R, Davies C, Godwin J et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 2012; 379; 432444.
  • 41
    Dowsett M, Nielsen TO, A'Hern R et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J. Natl Cancer Inst. 2011; 103; 16561664.
  • 42
    Mengel M, von Wasielewski R, Wiese B, Rudiger T, Muller-Hermelink HK, Kreipe H. Inter-laboratory and inter-observer reproducibility of immunohistochemical assessment of the Ki-67 labelling index in a large multi-centre trial. J. Pathol 2002; 198; 292299.
  • 43
    Hammond ME. ASCO–CAP guidelines for breast predictive factor testing: an update. Appl. Immunohistochem. Mol. Morphol. 2011; 19; 499500.
  • 44
    Tafjord S, Bohler PJ, Risberg B, Torlakovic E. Estrogen and progesterone hormone receptor status in breast carcinoma: comparison of immunocytochemistry and immunohistochemistry. Diagn. Cytopathol. 2002; 26; 137141.
  • 45
    Billgren AM, Tani E, Liedberg A, Skoog L, Rutqvist LE. Prognostic significance of tumor cell proliferation analyzed in fine needle aspirates from primary breast cancer. Breast Cancer Res. Treat. 2002; 71; 161170.
  • 46
    Ibrahim M, Dodson A, Barnett S, Fish D, Jasani B, Miller K. Potential for false-positive staining with a rabbit monoclonal antibody to progesterone receptor (SP2): findings of the UK National External Quality Assessment Scheme for Immunocytochemistry and FISH highlight the need for correct validation of antibodies on introduction to the laboratory. Am. J. Clin. Pathol. 2008; 129; 398409.
  • 47
    Gasparini G, Boracchi P, Verderio P, Bevilacqua P. Cell kinetics in human breast cancer: comparison between the prognostic value of the cytofluorimetric S-phase fraction and that of the antibodies to Ki-67 and PCNA antigens detected by immunocytochemistry. Int. J. Cancer 1994; 57; 822829.
  • 48
    Nofech-Mozes S, Vella ET, Dhesy-Thind S, Hanna WM. Cancer care ontario guideline recommendations for hormone receptor testing in breast cancer. Clin. Oncol. (R. Coll. Radiol.) 2012; 24; 684696.
  • 49
    Malaviya AA, Chinoy RF, Prabhudesai NM, Sawant MH, Parmar V, Badwe RA. Immunocytochemistry on scrape cytology in breast cancer: will it unearth the weaker positives? Acta Cytol. 2006; 50; 284290.
  • 50
    Nizzoli R, Bozzetti C, Savoldi L et al. Immunocytochemical assay of estrogen and progesterone receptors in fine needle aspirates from breast cancer patients. Acta Cytol. 1994; 38; 933938.
  • 51
    Radhika K, Prayaga AK. Estrogen and progesterone hormone receptor status in breast carcinoma: comparison of immunocytochemistry and immunohistochemistry. Indian. J. Cancer 2010; 47; 148150.
  • 52
    Konofaos P, Kontzoglou K, Georgoulakis J et al. The role of ThinPrep cytology in the evaluation of estrogen and progesterone receptor content of breast tumors. Surg. Oncol. 2006; 15; 257266.
  • 53
    Leung SW, Bedard YC. Estrogen and progesterone receptor contents in ThinPrep-processed fine-needle aspirates of breast. Am. J. Clin. Pathol. 1999; 112; 5056.
  • 54
    Nishimura R, Aogi K, Yamamoto T et al. Usefulness of liquid-based cytology in hormone receptor analysis of breast cancer specimens. Virchows Arch. 2011; 458; 153158.
  • 55
    Zoppi JA, Rotundo AV, Sundblad AS. Correlation of immunocytochemical and immunohistochemical determination of estrogen and progesterone receptors in breast cancer. Acta Cytol. 2002; 46; 337340.
  • 56
    Domanski AM, Monsef N, Domanski HA, Grabau D, Ferno M. Comparison of the oestrogen and progesterone receptor status in primary breast carcinomas as evaluated by immunohistochemistry and immunocytochemistry: a consecutive series of 267 patients. Cytopathology 2013; 24; 2125.
  • 57
    Lindstrom LS, Karlsson E, Wilking UM et al. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J. Clin. Oncol. 2012; 30; 26012608.
  • 58
    Vyberg M. Results from the NordiQC Ki67 web module. Newsletter. Available at: http://www.nordiqc.org: Nordic Immunohistochemical Quality Control; 25 July 2013.
  • 59
    Mikami Y, Ueno T, Yoshimura K et al. Interobserver concordance of Ki67 labeling index in breast cancer: Japan Breast Cancer Research Group Ki67 Ring Study. Cancer Sci. 2013; 104; 15391543.
  • 60
    Voros A, Csorgo E, Nyari T, Cserni G. An intra- and interobserver reproducibility analysis of the Ki-67 proliferation marker assessment on core biopsies of breast cancer patients and its potential clinical implications. Pathobiology 2013; 80; 111118.
  • 61
    Viale G. Pathological work up of the primary tumor: getting the proper information out of it. Breast 2011; 20(Suppl. 3); S82S86.
  • 62
    Harris L, Fritsche H, Mennel R et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J. Clin. Oncol. 2007; 25; 52875312.
  • 63
    Kuenen-Boumeester V, Timmermans AM, De Bruijn EM, Henzen-Logmans SC. Immunocytochemical detection of prognostic markers in breast cancer; technical considerations. Cytopathology 1999; 10; 308316.
  • 64
    Dowell SP, Lane DP, Hall PA. The immunocytochemical detection of p53 protein in cytological specimens: technical considerations. Cytopathology 1994; 5; 7681.
  • 65
    Burton SA, Dowsett M, Trott PA. Comparison of two methods of storing breast fine needle aspirates (FNAs) using oestrogen receptor immunocytochemical assay as a method of evaluating the storage methods. Cytopathology 1994; 5; 380383.
  • 66
    Donhuijsen K, Schmidt U, Hirche H, van Beuningen D, Budach V. Changes in mitotic rate and cell cycle fractions caused by delayed fixation. Hum. Pathol. 1990; 21; 709714.
  • 67
    Khoury T, Sait S, Hwang H et al. Delay to formalin fixation effect on breast biomarkers. Mod. Pathol. 2009; 22; 14571467.
  • 68
    Ferrer-Roca O, Ribera F, Sanchez L, Estevez M. Estradiol, progesterone and steroid receptors. Benign cycling versus malignant non cycling cells. Adv. Clin. Path 1997; 1; 7584.
  • 69
    Weimer DA, Donegan WL. Changes in estrogen and progesterone receptor content of primary breast carcinoma during the menstrual cycle. Breast Cancer Res. Treat. 1987; 10; 273278.
  • 70
    Haynes BP, Viale G, Galimberti V et al. Expression of key oestrogen-regulated genes differs substantially across the menstrual cycle in oestrogen receptor-positive primary breast cancer. Breast Cancer Res. Treat. 2013; 138; 157165.